EPZMUnknown
Epizyme, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Epizyme, Inc. (EPZM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are EPZM insiders buying or selling?
Epizyme, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2018, Trabud has recorded 51 Form 4 filings for EPZM: 5 buys ($39.3M) and 46 sells ($7.2M).
Source: SEC EDGAR Form 4
Key Statistics (February 2018 – Apr 13, 2022)
Total Form 4 filings
51
SEC EDGAR
Insider filers
10
Insider buys (5)
$39.3M
Insider sells (46)
$7.2M
Insider sentiment
Net buyingNet insider flow of $32.1M in net buying since February 2018.
Recent EPZM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 13, 2022 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.7K | $0.90 | $2.5K | SEC ↗ |
| Feb 9, 2022 | Joseph Beaulieu | Corporate Controller | Sale | 222 | $1.50 | $333 | SEC ↗ |
| Feb 9, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 1.1K | $1.50 | $1.6K | SEC ↗ |
| Feb 4, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 2.6K | $1.37 | $3.6K | SEC ↗ |
| Feb 4, 2022 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.6K | $1.37 | $3.5K | SEC ↗ |
| Feb 4, 2022 | Joseph Beaulieu | Corporate Controller | Sale | 687 | $1.37 | $941.19 | SEC ↗ |
| Feb 1, 2022 | Pablo G. Legorreta | Director, 10% Owner | Purchase | 22.7M | $1.50 | $34.0M | SEC ↗ |
| Jan 28, 2022 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 2.9K | $2.02 | $5.9K | SEC ↗ |
| Dec 8, 2021 | Shefali Agarwal | Executive Vice President, Chief Medical and Development Officer | Sale | 1.8K | $2.93 | $5.2K | SEC ↗ |
| Apr 7, 2021 | Jeffery Kutok | Chief Scientific Officer | Sale | 2.0K | $8.80 | $17.9K | SEC ↗ |
| Mar 29, 2021 | David M Mott | Director | Purchase | 62.7K | $7.97 | $500.1K | SEC ↗ |
| Mar 29, 2021 | Robert B Bazemore | President & CEO | Sale | 10.3K | $7.85 | $81.1K | SEC ↗ |
| Feb 5, 2021 | Robert B Bazemore | President & CEO | Sale | 3.9K | $11.21 | $43.6K | SEC ↗ |
| Feb 5, 2021 | Shefali Agarwal | Chief Medical Officer | Sale | 969 | $11.21 | $10.9K | SEC ↗ |
| Feb 5, 2021 | Paolo Tombesi | Chief Financial Officer | Sale | 1.0K | $11.21 | $11.4K | SEC ↗ |
| Feb 5, 2021 | Joseph Beaulieu | Corporate Controller | Sale | 227 | $11.21 | $2.5K | SEC ↗ |
| Feb 5, 2021 | Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | Sale | 894 | $11.21 | $10.0K | SEC ↗ |
| Feb 5, 2021 | Victoria Vakiener | Chief Commercial Officer | Sale | 817 | $11.21 | $9.2K | SEC ↗ |
| Jan 28, 2021 | Robert B Bazemore | President & CEO | Sale | 6.1K | $11.41 | $69.2K | SEC ↗ |
| Jan 28, 2021 | Matthew Ros | Executive Vice President, Chief Strategy & Business Officer | Sale | 2.9K | $11.41 | $32.8K | SEC ↗ |
| Jan 28, 2021 | Victoria Vakiener | Chief Commercial Officer | Sale | 599 | $11.41 | $6.8K | SEC ↗ |
| Jan 28, 2021 | Shefali Agarwal | Chief Medical Officer | Sale | 2.9K | $11.41 | $32.8K | SEC ↗ |
| Dec 7, 2020 | Shefali Agarwal | Chief Medical Officer | Sale | 2.5K | $13.54 | $34.1K | SEC ↗ |
| Nov 13, 2020 | Carl Goldfischer | Director | Purchase | 5.0K | $12.07 | $60.4K | SEC ↗ |
| Sep 4, 2020 | Joseph Beaulieu | Corporate Controller | Sale | 1.5K | $12.81 | $19.4K | SEC ↗ |
Showing the 25 most recent of 51 Form 4 filings for Epizyme, Inc..
Most active EPZM insiders
- Shefali Agarwal11 filings
- Joseph Beaulieu9 filings
- Matthew Ros8 filings
- Robert B Bazemore8 filings
- David M Mott5 filings
Ask anything about EPZM insider activity
Use Trabud's AI agent to query Epizyme, Inc.'s Form 4 history in plain English — "Show me EPZM CEO purchases this year" or compare it against any other ticker.
Open the AI agentEPZM insider trading FAQ
Are Epizyme, Inc. insiders buying or selling?
Epizyme, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since February 2018, Trabud has recorded 51 Form 4 filings for EPZM: 5 buys ($39.3M) and 46 sells ($7.2M). Over the full record that is net buying of $32.1M.
How many insiders trade EPZM stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Epizyme, Inc.. The most recent filing was accepted on Apr 13, 2022.
Where does Trabud get EPZM insider trading data?
All EPZM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.